April 6 (Reuters) - Alar Pharmaceuticals Inc 6785.TWO:
ALAR BREAKS KEY BARRIERS IN KETAMINE THERAPY WITH POSITIVE PHASE 1 RESULTS FOR LONG-ACTING INJECTABLE ALA-3000 FOR TREATMENT-RESISTANT DEPRESSION
ALAR PHARMACEUTICALS INC - ALA-3000 MEETS PRIMARY ENDPOINT WITH FAVORABLE SAFETY AND TOLERABILITY PROFILE
ALAR PHARMACEUTICALS INC - NO CLINICALLY MEANINGFUL SAFETY CONCERNS IDENTIFIED FOR ALA-3000
ALAR PHARMACEUTICALS INC - NO DISSOCIATION, SEDATION, OR PSYCHOSIS-LIKE SYMPTOMS OBSERVED WITH ALA-3000